| ¿ Por qué las innovaciones en el desarrollo de fármacos para la enfermedad inflamatoria intestinal afectarán a la práctica clínica? WJ SANDBORN | | |
| " PSC-IBD": A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. GC Harewood, EV Loftus, WJ Tremaine, WJ Sandborn Gastroenterology 116 (4), A732-A732, 1999 | 8 | 1999 |
| 04 DIAGNOSTIC ACCURACY OF THE SERUM-BASED MUCOSAL HEALING INDEX ASSAY IN CROHN’S DISEASE AND COMPARATIVE ACCURACY TO FECAL CALPROTECTIN IN ROUTINE PRACTICE R Battat, B Boland, S Singh, A Collins, ER Evans, MA Valasek, A Jain, ... Gastroenterology 156 (3), S20, 2019 | 1 | 2019 |
| 10 Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D: Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994; 343: 766–767. 11 Hooper LV, Wong MH, Thelin A … DP Jewell, D Rachmilewitz, DB Sachar, WJ Sandborn, LR Sutherland Inflammatory Bowel Disease Principles and Practice 20, 355, 2003 | | 2003 |
| 1003–Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease BE Sands, WJ Sandborn, L Peyrin-Biroulet, PD Higgins, F Hirai, R Belin, ... Gastroenterology 156 (6), S-216, 2019 | 17 | 2019 |
| 1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD). SB Hanauer, JF Colombel, WJ Sandborn, BE Sands, S Schreiber, ... Gastroenterology 164 (6), S-221, 2023 | 1 | 2023 |
| 1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) S Travis, WJ Sandborn, SB Hanauer, M Lemann, BE Sands, P Marteau, ... Gastroenterology (New York, NY 1943) 136 (5), A-160-A-160, 2009 | 5 | 2009 |
| 11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind … B Sands, B Feagan, P Rutgeerts, JF Colombel, W Sandborn, R Sy, ... Journal of Crohn's and Colitis 7 (Supplement_1), S5-S6, 2013 | 19* | 2013 |
| 110 Stool DNA Methylation Markers for the Detection of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease JB Kisiel, TC Yab, WR Taylor, JA Simonson, M Garrity-Park, FTN Hussain, ... Gastroenterology 5 (142), S-26-S-27, 2012 | 2 | 2012 |
| 12-month steroid-sparing results of natalizumab in a controlled study of patients with Crohn's disease JF Colombel, R Enns, B Feagan, S Hanauer, I Lawrance, R Parraccione, ... Gastroenterology 128 (4), A576-A576, 2005 | 2 | 2005 |
| 129 Safety of Ustekinumab In IBD: Pooled Safety Analysis through 5 years in CD and 2 Years in UC WJ Sandborn, BG Feagan, E Ott, C Gasink, JP Lynch, CW Marano, ... Gastroenterology 160 (6), S-35-S-36, 2021 | 11 | 2021 |
| 132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE BE Sands, WJ Sandborn, L Peyrin-Biroulet, PD Higgins, F Hirai, V Jairath, ... Gastroenterology (New York, NY 1943) 160 (6), S-37-S-37, 2021 | 12 | 2021 |
| 143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in … WJ Sandborn, S Vermeire, GR D'Haens, JF Colombel, RN Fedorak, ... Gastroenterology 5 (136), A-27, 2009 | 18 | 2009 |
| 16 Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial L Peyrin-Biroulet, W Reinisch, JF Colombel, GJ Mantzaris, A Kornbluth, ... Journal of Crohn's and Colitis 7 (Supplement_1), S8-S8, 2013 | 2 | 2013 |
| 16 THERAPY rransdermal nicotine beneficial in ulcerative colitis WJ Sandborn, WJ Tremaine, KP Offord, OM Lawson, BT Petersen Internal Medicine 126, 364-371, 1997 | | 1997 |
| 195 HLA Class II Genotype Predicts Increased Risk for Ulcerative Colitis-Associated Colorectal Cancer and Correlates with Methylation of the MHC Class II Transactivator (Ciita … M Garrity-Park, EV Loftus, WJ Sandborn, SC Bryant, TC Smyrk Gastroenterology 4 (134), A-34, 2008 | 1 | 2008 |
| 1University of California, San Diego, La Jolla, United States, 2Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Lille, France, 3University of Liege and CHU … W Sandborn, JF Colombel, E Louis, R Panaccione, M Yang, J Chao, ... Inflammatory Bowel Disease Clinic, Calgary, Canada, 5Abbott Laboratories …, 0 | 4 | |
| 209 Prospective therapeutic drug monitoring to optimizing infliximab (IFX) maintenance therapy in patients with inflammatory bowel disease (IBD) BP Vaughn, M Martínez-Vazquez, V Patwardhan, AC Moss, WJ Sandborn, ... Gastroenterology 5 (146), S-54, 2014 | 11 | 2014 |
| 209–Early Combined Immunosuppression is Effective and Safe in Older Patients with Crohn's Disease: Post-Hoc Analysis of React Cluster Randomized Trial S Singh, L Stitt, G Zou, R Khanna, PS Dulai, WJ Sandborn, BG Feagan, ... Gastroenterology 156 (6), S-43-S-44, 2019 | | 2019 |
| 211 A Pilot Study of Optimized Monotherapy With Infliximab for Patients With Inflammatory Bowel Disease BP Vaughn, M Martínez-Vazquez, V Patwardhan, AC Moss, WJ Sandborn, ... Gastroenterology 146 (5), S-55, 2014 | 1 | 2014 |
